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Summary Forty-two patients with hepatocellular carcinoma (HCC) were resected and their tumours were analysed forp53mutations by GC-
clamped denaturing gradient gel electrophoresis (DGGE), single-strand conformation polymorphism (SSCP) and gene sequencing. All the
exons have been analysed in this study. Eight of 12 HCCs with cirrhosis due to viral hepatitis and the two patients with sarcomatoid changes
displayed p53 mutations. In contrast, no mutation was observed in the fibrolamellar variant (n = 9), non-cirrhotics (n = 13) and alcoholic
cirrhosis (n = 6). The mutations observed were in exons 5-8. Two mutations were observed in codons 136 and 213 as well as a T insertion
between residues 156 and 157 (exon 5) and these are reported forthe first time in HCC. Likewise, the silent mutation polymorphism in codon
213 was noticed in 3 ofthe 42 patients. Survival analysis ofthese patients after surgery showed the mean and median survival in patientswith
wild-type p53 to be 60 and 43 months respectively. In the group with p53 mutations, the mean and median survival was 15 and 12 months.
The difference was statistically significant (P= 0.003).
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p53 protein is a DNA-binding, cell-regulating transcription factor
that has multiple critical roles in the complex pathway governing
cell cycle and in the balance between cell division and apoptosis.
Losses and/or mutations of p53 play a crucial role in a large
number ofmalignancies.
Thep53 gene is the most commonly mutated tumour-suppressor
gene in various human cancers (Nigro et al, 1989), and it has been
reported in hepatocellular carcinomas (HCCs). However, most of
these reports studied patients from eastAsian countries and Africa,
where viral hepatitis and aflatoxins are rather prevalent in contrast
to Western countries. We examined 42 primary liver carcinoma
specimens, which were surgically resected at the Hammersmith
Hospital (UK) with histologically confirmed diagnosis, for muta-
tion of the p53 gene by denaturing gradient gel electrophoresis
(DGGE), single-strand conformation polymorphism (SSCP) and
sequence analysis.
The aim of this investigation was to study the presence ofp53
mutation in HCC patients without viral hepatitis, such as those
with the fibrolamellar variant, alcoholic cirrhosis or the classical
non-cirrhotic HCC patients. In addition, we aimed to find out
whether p53 mutation could influence survival after surgical
resection in these patients.
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PATIENTS AND METHODS
Forty-two patients with HCC were studied, of whom nine had the
fibrolamellar variant ofHCC. Eighteen ofthe 42 HCC patients had
underlying cirrhosis (six alcoholic, 12 non-alcoholic). The 12
patients with non-alcoholic cirrhosis had serological evidence of
viral infection (two were HBs antigen and HcVAb positive, seven
were HCV antibody positive and three were HBs antigen and HCV
antibody positive). The remaining 13 had non-cirrhotic HCC
tumours. A further two patients had sarcomatoid transformation of
hepatocellular carcinoma (Kakizoe et al, 1987). The study included
14 women and 28 men with a mean age of54.6 years (range 14-73
years). All patients underwent surgical resection of their tumours.
None of the patients had any preoperative chemotherapy. Tumour
tissue samples as well as surrounding non-tumorous liver tissue
samples were obtained at the time ofoperation. The tissue samples
were fixed in 10% neutral formalin and subjected to histopatho-
logical examination. A portion of each specimen was frozen in
liquid nitrogen immediately after resection and stored at - 70°C
until DNA extraction. DNA was prepared from tissue specimens by
standard phenol-chloroform methods (Sambrook et al, 1989).
PCR amplification for the DGGE study
Primers flanking p53 exon sequences were prepared according to
the previous report (Beck et al, 1993). One microgram ofgenomic
DNA was mixed with 50 pmol ofeach appropriate oligonucleotide
primer and with 0.2 mmol 1-1 ofeach deoxyribonucleotide triphos-
phate and 1.5 units of Taq DNA polymerase (Bioline), in 50pl of
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Figure 1 Exon 5 mutation 5. (A) Exon 5 PCR product SSCP analysis of cases 1 and 9 (C, control). (B) Direct sequencing. The T insertion (case 1) determines
the shift of the sequencing pattern of the mutated allele (compare normal and tumoral sequences). In case 9, a C -* T transition produces a non-sense
mutation. The homozygous state of case 9 is evident in both experimental approaches
its standard 'potassium chloride' buffer. Samples were incubated
in a DNA thermal cycler (GeneAmp PCR system 2400, Perkin-
Elmer) for atotal of40 cycles at 94°C, 58°C, 72°C for 30 s at each
temperature. Four microlitres of the polymerase chain reaction
(PCR) products were subjected to electrophoresis on a 2% agarose
gel to examine successful amplification ofeach fragment.
DGGE
The optimum gradient for each PCR product was determined with
perpendicular DGGE according to the manufacturer's instructions
(D-Gene Denaturing Gel Electrophoresis System, Bio-Rad). The
ranges of denaturant of parallel DGGE and the optimum condi-
tions of electrophoresis were previously reported (Beck et al,
1993). Gels were stained with ethidium bromide and were
photographed using Polaroid film.
PCR and single-strand conformation polymorphism
analysis
Primers for DNA amplification of the complete coding region,
including exon-intronjunctions, were appropriately selected from
the humanp53 gene sequence (Lamb and Crawford, 1986).
The reaction mixture contained 100 ng of genomic DNA,
30 pmol of appropriate oligonucleotide primer pairs, 0.1 mm
dNTPs, 50 mm potassium chloride, 1.5 mm magnesium chloride,
10 mM Tris-HCI pH 9, 2.5 U ofTaq DNA Pol (Pharmacia Biotech)
in a total volume of 100gl. In each set of PCR reactants, a nega-
tive no-template control was included. The amplified products
were purified to eliminate primers and non-specific products on
2% agarose Tris-borate-EDTA (TBE) gel. The appropriate band
was cut out from the gel and eluted by QlAquick Gel Extraction
kit (Qiagen).
Five microlitres ofPCR product (300 ng) were mixed with 2gl
of 1% sodium deoxycholate, 2 pl ofEDTA 0.11 M pH 7.5 and 5 gl
of loading buffer (deionized formamide 98%, 2gl of EDTA 0.11
pl of bromophenol blue-xylene cyanol 0.3%). The samples were
boiled for 5 min and immediately subjected to electrophoresis on
non-denaturing polyacrylamide gel; 8 x 10 cm 0.75-thick poly-
acrylamide gels and0.5 x TBEpH 7.5 running buffer wereused. A
constant internal buffer temperature was maintained during the gel
run. Gels were run at 200 V for 1-4 h, depending on the fragment
size and gel percentage.
Afterelectrophoresis, the gels were silverstained anddrieddown.
Codon 213 and 249 restriction analyses
An aliquot of exon 6 PCR product was digested with Taq I restric-
tion endonuclease at 650C for 2 h to identify 213 mutation.
Substitution of any bases ofcodon 213 results in the loss of a Taq I
site, while the PCR product of the wild type is digested into 140-
and 96-bp fragments.
An aliquot of exon 7 PCR product was digested with HaeIII at
37°C for 2 h to identify 249 mutation (data not shown).
Manufacturer-provided buffers and instructions were used. The
digested DNAs were electrophoresed on a 1.5% agarose gel and
the DNA was visualized by ethidium bromide staining.
Sequence
Exons showing an altered migration in SSCP and DGGE were
sequenced both with forward and reverse primers to confirm the
mutations on both strands. When the tumour was identified to have
a mutation, the p53 sequence ofthe non-tumorous livertissue from
the same individual was also evaluated. Sequence compression
problems, as a result of the high G-C content in the gene, were
solved by using modified nucleotides, such as deazanucleotides
and inosine and controlled temperature conditions in electro-
phoretic running.
Sequencing primers were the same as those used for SSCP. A
cycle-sequencing kit (Perkin Elmer) and [35Sd]ATP were used for
sequencing. The products reaction was electrophoresed on a dena-
turing 6% polyacrylamide-7 M urea gel according to the manufac-
turer's instructions.
The survival data of all these patients after hepatectomy were
collected prospectively and were analysed using the log-rank test.
RESULTS
Two patients (cases 1 and 9) had mutation in exon 5 as shown in
the SSCP analysis (Figure IA). Direct sequencing showed that
case no. 1 had a T insertion between residues 156 and 157 (Figure
IB). Sequencing analysis of case no. 9 showed a mutation ofcodon
136, CAA-TAA with a substitution from glutamine to a stop codon
(Figure iB). The tumour of this patient had sarcomatoid change,
which is thought to be a more aggressive variant ofHCC.
DGGE analysis of exon 6 offour patients (cases 2, 3, 4 and 10)
showed in the tumoral samples a complex deviated pattern
compared with the control (Figure 2). Case 4 had deviated bands
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Figure 2 Exon 6 mutations. DGGE in tumour (A) and non-tumoral tissue
(B) in cases 2, 3, 4 and 10 showing mutations and constitutional
polymorphism (wt, wild type)
only in the tumoral tissue. Whereas cases 2, 3 and 10 showed in
the non-tumoral liver samples some of the deviated bands that
were present in their tumoral counterparts. Sequencing analysis
revealed that all four patients had a mutation in codon 213. The
sequencing oftumoral andnon-tumoral tissues ofcases 2, 3 and 10
revealed a germline polymorphism due to a silent substitution of
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Figure 3 Exon 6 mutations. (A) Codon 213 restriction analysis. Taq I-
restricted exon 6 PCR products (236 bp) of cases 10, 2, 3 and 4. C, Control;
B, blood, T, tumoral, N, non-tumoral. Taq digests the wild-type (wt) DNA into
two fragments of 140 and 96 bp. Substitution of any bases in the codon 213
determines the loss of the restriction site. Cases 10, 2 and 3 have a germline
polymorphism, present in tumoral and non-tumoral DNA. Case 4 has a
homozygous mutation in tumoral DNA. The type of mutation is assessed by
sequencing. (B) Codon 213 direct sequencing analysis. Case 3: the germline
polymorphism is a silent substitution of the third codon position. The same
substitution is present in cases 10 and 2 (sequencing data not shown). Case
4: the mutation is a missense mutation of the second codon position. (C)
Direct sequencing. Cases 10 and 2 have a non-sense mutation in codon 204
and 196, respectively, beside the 213 germline polymorphism
the third position ofcodon 213 (CGA-CGG) resulting in no amino
acid changes (Figure 3B). Case 4 had a missense mutation
(Arg-Leu) due to a G-T transversion in the second position of
codon 213 (CGA-CTA). Mutation of any base of codon 213
results in the loss ofthe Taq I site. As shown in Figure 3A, cases 2,
3 and 10 had a heterozygous germline substitution both in the
tumoral and non-tumoral tissue. Case 4, instead, had a homo-
zygous mutation only in the tumoral liver.
The sequencing of cases 2 and 10 revealed two non-sense
mutations in the tumoral tissue at codon 196 (Arg -< stop) and
204 (Glu -* stop), respectively (Figure 3C), besides the 213
polymorphism.
As for exon 7, three tumour samples (cases 5-7) showed devi-
ated bands in SSCP analysis (Figure 4A). HaeIII analysis revealed
that two ofthem (cases 6 and 7) had codon 249 mutation after the
loss of the restriction site (data not shown). Sequence analysis
showed a missense mutation AGG-AGT leading to amino acid
substitution from arginine to serine (Figure 4B). Sequencing and
HaeIII digestion suggest that case 6 had a mutation in the homozy-
gous state. Case 5 had a missense mutation GGC-TGC leading to
amino acid substitution from glycine to cysteine (Figure 4B).
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Figure 4 Exon 7 mutations. (A) Exon 7 PCR product SSCP analyses of cases 5, 6 and 7 (C, control; M, size marker). (B) Direct sequencing. Case 5 has a
missense mutation in codon 245. Cases 6 and 7 have a missense mutation in codon 249. The homozygous state of case 6 is evident in both experimental
approaches
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Figure 5 Exon 8 mutations. Direct sequencing. Case 8 has a non-sense
mutation in codon 294
One tumour sample (case 8) showed a deviated band in exon 8
in DGGE (data not shown). Sequencing revealed that the patient
had a non-sense mutation ofcodon 294 (Glu-stop) (Figure 5).
Of all the mutated samples, three showed a single mutant band
in sequencing gel (cases 4, 6 and 9) which most probably repre-
sents a homozygous state resulting from the pairing of a mutant
allele with a deletion in the remaining allele.
The homozygous state of case 4 was supported by Taq I diges-
tion, of case 6 by HaeIII digestion (data not shown) and by SSCP,
and of case 9 by SSCP.
In the remaining cases, the sequencing gels, the SSCP and the
restriction analyses revealed both the mutant as well as the
wild-type bands. These tumours may have a p53 mutation but no
Table 1 p53 mutation and clinical diagnosis
Diagnosis Number p53mutation Mutation
of patient frequency
Exon 5 Exon 6 Exon 7 Exon 8
Fibrolamellar carcinoma 9 0 0 0 0 0/9 (0)
HCC without cirrhosis
No viral infection 12 0 0 0 0 0/12 (0)
Viral infection 1 0 0 0 0 0/1 (0)
HCC with cirrhosis
Alcoholic 6 0 0 0 0 0/6 (0)
Viral hepatitis 12 1 3 3 1 8/12 (57)
HCC with sarcomatoid 2 1 1 0 0 2/2 (100)
Total 42 2 4 3 1 10/42 (22)
Numbers in parentheses are percentages.
Table 2 p53 mutation and viral infection of the cirrhotic liver
Infection Number p53 mutation Mutation
of patient frequency
Exon 5 Exon 6 Exon 7 Exon 8
HB 2 0 1 0 0 1/2
HCV 7 1 2 3 0 6/7
HB+HCV 3 0 0 0 1 1/3
Total 12 1 3 3 1 8/12
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Figure 6 Survival of patients with p53 mutations (-, Group 1) and those
with wild-type p53 (- - -, Group 2)
deletion of the remaining wild-type p53 allele, alternatively the
wild-type band may be derived from the contamination of tumour
DNAby the non-tumoral stroma or liver DNA.
The detected mutations were searched against the p53-special-
ized database (Hollstein etal, 1994), through the Internet, allowing
the comparison of results obtained against those collected in the
database. This database was a compilation of 4500 p53 mutations
in human tumour cells and cell lines from a systematic search of
reports published before 1 January 1994 (release 1995) and is
available at the EBI (UK).
We have found that the T insertion of case 1 has never been
reported before; the Arg-Leu substitution (codon 213) of case 4
and the Gln-stop mutation (codon 136) of case 9 have never been
reported previously in HCC.
p53 mutation and clinical profiles
The overall results are shown in Table 1. One of 13 patients with
HCC without cirrhosis was HB antigen positive, with no
histopathological findings ofhepatitis. No mutation was detected
in fibrolamellar variants, HCCs without cirrhosis and HCCs with
alcoholiccirrhosis. Eight of 12 HCCs with cirrhosis due to viral
hepatitis had mutations of the p53 gene, one in exon 5, three in
exon 6, three in exon 7 and one in exon 8 (Table 1). Both HCCs
with sarcomatoid change had mutations in exons 5 and 6. Table 2
shows the relationship between the mutations and the infectious
status of the cirrhotic livers. There was no significant difference
between HBV and HCV infection.
Survival data
Survival data after liver resection showed that the mean and the
median survival in patients with wild-type p53 were 60 and 43
monthsrespectively. In thegroup withp53 mutation, the mean and
median survival were 15 and 12 months. The difference was statis-
tically significant (P = 0.0034) (Figure 6).
The data for HCC patients with and withoutp53 mutations were
also analysed, excluding those patients with the fibrolamellar
variant. Survival in the HCCpatients without mutations (median 43
months) washigherthan that inpatients with mutation (P = 0.0023).
DISCUSSION
In this study, a group of 42 patients was analysed. Ten patients
showed somatic single nucleotide substitutions and two of them
also showed a germline polymorphism (cases 2 and 10). All the
mutations identified in our study were in the core domain, which
contains the sequence-specific DNA binding activity of the p53
protein (residues 102-292), critical for the biological activity of
the protein.
In case 1, the mutation, never reported before, is a T insertion
between residues 156 and 157 (exon 5). Insertion events are more
rare mutations and determine the frameshift of the mRNA and
consequent translational truncation.
Four are non-sense mutations (cases 2, 8-10). They occur in
exon5 (codon 136), exon 6 (codons 196, 204) and exon 8 (codon
294). The wild-type codons change to stop codons TAA, TAG or
TGA generating truncated p53 products. These incomplete prod-
ucts contain the core domain but lack the oligomerization domain
located near the carboxyl-terminal portion (residues 316-364).
This domain is extremely important in the tetramerization of
protein monomer subunits. Structural studies have demonstrated
that the core domain alone binds, as a monomer, to DNA with
sequence specificity and affinity similar to that of complete p53,
however the formation of the tetramer is a crucial event for p53
function (Cho et al, 1994).
Four are missense mutations (cases 4-7) resulting in amino acid
substitutions. They occur in exon 6 (codon 213) and exon 7
(codons 245 and 249). Arg 249 and Gly 245 have been demon-
strated, bycrystal study, toplay a critical role, stabilizing the struc-
ture ofthe DNA binding surface ofp53. These residues have a key
role in the backbone conformation of p53, allowing hydrogen
bonds with other amino acid residues (Cho et al, 1994). Changes
of these amino acids disrupt the folding of the protein.
In addition, functional approaches have demonstrated that the
substitution at mutational hot spot residues 249 and 213 resulted in
loss of DNA binding and loss of transcriptional activity of a
reporter gene carrying a p53-binding site in S. cerevisiae (Thukral
et al, 1994). Mutation ofArg 249 determines the loss ofthe HaeII
restriction site. Arg 213 is involved in two different mutational
events: a silent substitution (cases 2, 3 and 10) and a missense
mutation (case 4). The presence ofboth type of mutations is easily
detectable by restriction enzyme digestion. Changing of any base
of the residue 213 determines the loss of the Taq I restriction site.
The type ofmutation was assessed by sequencing.
The variant CGA-CGG silent third position alteration resulted
in no amino acid changes. This variant was detected both in
normal and in tumoral tissue and thus represents a naturally occur-
ring germline polymorphism at codon 213. This polymorphism
has been reported in literature and is estimated to occur in 3.5% of
the worldwide population but is found in about 10% of the Italian
population (Serra et al, 1992). Thecorrelation of this silent variant
with cancer and other degenerative processes (e.g. atherosclerotic
lesions; D'Agostini et al, 1995) is not known.
Of all the mutations we have characterized, four involve anArg.
Structurally, arginine takes part in basic interactions. Its sidechains
participate in van der Waals, electrostatic and hydrogen bonding
interactions with other sidechains with back-bone carbonyl groups
(Cho et al, 1994).
As far as the nucleotide substitutionpattern, six are G-T trans-
versions, two are C-T transitions and two are A-G transitions. G
to T transversion is caused by both exogenous carcinogens and
endogenous processes, such as free radical damage arising from
normal biochemical reactions in mouse and monkey (Adelman et
al, 1988). Two mutations involve CpG pairs (residues 196 and
213). CpG sites are preferential targets for point mutations in
different mammaliangenes during theprocess ofDNA replication,
presumably due to spontaneous deamination of methylated
cytosine residues (Abadie et al, 1989).
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Our data clearly show that the presence of viral hepatitis is
related to mutations of the p53 gene of HCCs with cirrhosis.
Epidemiological evidence indicates that hepatitis B and C viruses
are involved in the aetiology ofHCC (Robinson, 1994).
Indirect evidence suggests that most HCC may be a response to
general effects of perisistent viral HBV and HCV infection of
hepatocytes, which leads to chronic liver injury that initiates other
events, including hepatocellular necrois, inflammatory response
and hepatocellular proliferation associated with liver regeneration
(necroinflammatory liver disease). The continuation of the
necroinflammatory process for many years commonly leads to
cirrhosis and therefore greatly increases the risk ofHCC develop-
ment. Regeneration of liver cells through chronic hepatitis
increases the incidence of genetic alterations in hepatic cells
and/or HCCs in both HBV- and HCV-infected patients.
A direct viral oncogenic mechanism has not been definitely
established for any HCC in HBV-infected humans. However, it
was reported that HBV may act as a non-selective insertional
mutagenic agent. Indeed, chronic hepatitis B infections leads to
viral integration, at random sites, into the hepatocyte DNA and is
frequently associated with deletions, mutations and rearrange-
ments of genomic DNA near the site of integration. Two HCCs
have been reported with deletions in l7pl3 with loss of p53 and
HBV integration at that site (Hino et al, 1986; Slagle et al, 1991).
Furthermore, after integration of viral DNA, overexpressed HBV
gene products (HBx, MHBst) have the capacity to function as tran-
scriptional transactivators. They may alter signal transduction
pathways important for the regulation of cell growth during
hepatocellular regeneration and compromise cellular DNA repair
processes (Feitelson and Duan, 1997). All these events contribute
to genomic instability and to hepatocarcinogenesis.
There are many reports on the frequency ofmutations ofthep53
gene of HCC. High frequency of the mutation at codon 249 in
exon 7 was reported from China (Hsu et al, 1991) and South
Africa (Bressac et al, 1991), where patients were exposed to high
levels ofaflatoxin B (AFB1). In our study, only two HCCs had this
specific mutation. In Japan, Nose et al (1990) reported that alter-
ations associated with the p53 gene were found in 6 of 20 HCCs
(30%). Likewise, Nishida et al (1993), and Hayashi et al (1995)
also reported that the frequency was 32% and 27.8%, respectively,
in Japan. No mutational hot spot has been reported in these
studies, suggesting the involvement of different aetiological
factors from AFB1. Buetow et al (1992) analysed 107 HCCs from
geographically and ethnically diverse sources. They reported that
the mutation rate of tumours from high AFB1-exposure regions
was 25% and that in low-exposure regions was 12%. In our study,
the overall mutation rate was 22%. However, the mutation rate of
the HCCs with cirrhosis due to viral hepatitis was very high
(66%). Hosono et al (1991) reported infrequent mutation of the
p53 gene (18%) in hepatitis B virus-positive primary HCCs from
Taiwan. Shieh et al (1993) also suggested that p53 mutations may
not play a significant role in HCV- or HBV-associated hepato-
carcinogenesis. However, Teramoto et al (1994) reported that
patients infected with either HBV or HCV showed an incidence
of p53 abnormalities (45%) higher than those infected by
neither (13%).
Our results suggest a close relationship between p53 mutations
in HCCs and cirrhosis due to viral hepatitis. Fibrolamellar vari-
ants, HCCs without cirrhosis and HCCs with alcoholic cirrhosis
had nop53 mutations but had different aetiology from HCCs with
viral hepatitis.
Sarcomatoid liver carcinoma is an uncommon form of liver
tumour and the incidence of sarcomatoid changes in primary liver
cancers is reported to be 2.2-3.9%. Previously, we reported that
the tumours of the two patients studied had multiple allelic losses
detected by loss ofheterozygosity (LOH) analysis using 25 restric-
tion fragment-length polymorphism (RFLP) probes for 15
different chromosomes (Ding et al, 1993a). Bothpatients had large
undifferentiated tumours, extensive local invasion and local recur-
rence and both died within 6 months of the operation from
multiple lung metastases. It is quite likely that the p53 gene was
also involved in these multiple genetic changes that led to the poor
outcome in these two patients.
Fibrolamellar carcinoma is a rare variant ofhepatocellular carci-
noma (HCC). It occurs in youngerpatients (aged 20-30 years) with
an equal sex incidence. Cirrhosis and hepatitis B and C viruses are
rarely seen in patients with FLC, and it is thought that the tumour
may arise from areas of focal nodular hyperplasia (Vecchio et al,
1984). The prognosis of patients with FLC is better than that of
those with HCC. All thepatients in this series with this variant who
were operated are still alive and none ofthem havep53 mutations.
This is in contrast to the two patients with sarcomatoid changes and
with p53 mutations, both died of tumour recurrence within 6
months. Previously, in a loss of heterozygosity study using 25
RFLP probes for chromosomes 1-5, 7, 9, 11-14, 16-18 and 20 we
found 3.6% allele loss in fibrolamellar HCC (Ding et al, 1993b) vs
16.1% cirrhotic and non-cirrhotic HCC (Ding et al, 1991) and
56.2% in sarcomatoid HCC (Ding et al, 1993a).
There are several reports on the relationship between mutations
ofthep53 gene and poorerprognosis. Hayashi et al (1995) reported
that the presence ofp53 mutations in HCCs was associated with a
shortened cancer-free survival and a shortened survival.
Likewise, in this study, we found p53 to be a poor prognostic
indicator for survival in patients undergoing liver resection. Future
studies may show that tumour staging could include the preopera-
tive determination ofp53 status in these patients. The presence of
p53 mutation might discourage surgeons to consider resection and
might be a favourable criteria for inclusion in gene replacement
therapy (Habib et al, 1996).
In this study, DGGE was more reliable than SSCP in detecting
p53 mutations. All four patients with exon 6 mutations were
missed by SSCP. On the otherhand DGGE and SSCP were equally
sensitive in identifying all patients with mutations in exons 5, 7, 8
and 9. To streamline experiments for exons 1-4 10 and 11, only
SSCP was used.
In conclusion,p53 mutations occur mainly in the group ofHCC
patients with liver cirrhosis associated with viral hepatitis and is a
poor prognostic indicator for survival after liver resection.
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